{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:20:48Z","timestamp":1788283248130,"version":"build-2803163510"},"reference-count":320,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01513-4","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:27:35Z","timestamp":1788276455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Solute carrier membrane transporters: emerging targets in CNS disorders"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6255-774X","authenticated-orcid":false,"given":"Yee Kwan","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-3783","authenticated-orcid":false,"given":"Selene","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-2723","authenticated-orcid":false,"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-6987","authenticated-orcid":false,"given":"Ariel","family":"Bensimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-2223","authenticated-orcid":false,"given":"S. Andreas","family":"Angermayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-1768","authenticated-orcid":false,"given":"Giulio","family":"Superti-Furga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan, P. & Brodie, M. J. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314\u2013319 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1513_CR2","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1021\/acs.jmedchem.9b01237","volume":"63","author":"WW Wang","year":"2020","unstructured":"Wang, W. W., Gallo, L., Jadhav, A., Hawkins, R. & Parker, C. G. The druggability of solute carriers. J. Med. Chem. 63, 3834\u20133867 (2020).","journal-title":"J. Med. Chem."},{"key":"1513_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/d41586-024-02435-0","volume":"632","author":"HH Sitte","year":"2024","unstructured":"Sitte, H. H. Structures of the dopamine transporter point to ways to target addiction and disease. Nature 632, 509\u2013511 (2024).","journal-title":"Nature"},{"key":"1513_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17460441.2023.2244760","volume":"18","author":"V Dvorak","year":"2023","unstructured":"Dvorak, V. & Superti-Furga, G. Structural and functional annotation of solute carrier transporters: implication for drug discovery. Expert Opin. Drug Discov. 18, 1099\u20131115 (2023).","journal-title":"Expert Opin. Drug Discov."},{"key":"1513_CR5","doi-asserted-by":"publisher","first-page":"105096","DOI":"10.1016\/j.isci.2022.105096","volume":"25","author":"E Ferrada","year":"2022","unstructured":"Ferrada, E. & Superti-Furga, G. A structure and evolutionary-based classification of solute carriers. iScience 25, 105096 (2022).","journal-title":"iScience"},{"key":"1513_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271062","volume":"17","author":"G Gyimesi","year":"2022","unstructured":"Gyimesi, G. & Hediger, M. A. Systematic in silico discovery of novel solute carrier-like proteins from proteomes. PLoS ONE 17, e0271062 (2022).","journal-title":"PLoS ONE"},{"key":"1513_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2025.01.015","volume":"188","author":"A Khan","year":"2025","unstructured":"Khan, A., Liu, Y., Gad, M., Kenny, T. C. & Birsoy, K. Solute carriers: the gatekeepers of metabolism. Cell 188, 869\u2013884 (2025).","journal-title":"Cell"},{"key":"1513_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00424-003-1192-y","volume":"447","author":"MA Hediger","year":"2004","unstructured":"Hediger, M. A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflug. Arch. 447, 465\u2013468 (2004).","journal-title":"Pflug. Arch."},{"key":"1513_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s44320-025-00108-2","volume":"21","author":"U Goldmann","year":"2025","unstructured":"Goldmann, U. et al. Data- and knowledge-derived functional landscape of human solute carriers. Mol. Syst. Biol. 21, 599\u2013631 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"1513_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1146\/annurev-biochem-060815-014520","volume":"85","author":"D Drew","year":"2016","unstructured":"Drew, D. & Boudker, O. Shared molecular mechanisms of membrane transporters. Annu. Rev. Biochem. 85, 543\u2013572 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"1513_CR11","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli, M. D., Bensimon, A. & Superti-Furga, G. A guide to plasma membrane solute carrier proteins. FEBS J. 288, 2784\u20132835 (2021).","journal-title":"FEBS J."},{"key":"1513_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s42255-022-00645-2","volume":"4","author":"L Bar-Peled","year":"2022","unstructured":"Bar-Peled, L. & Kory, N. Principles and functions of metabolic compartmentalization. Nat. Metab. 4, 1232\u20131244 (2022).","journal-title":"Nat. Metab."},{"key":"1513_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s42255-021-00386-8","volume":"3","author":"K-C Li","year":"2021","unstructured":"Li, K.-C. et al. Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states. Nat. Metab. 3, 651\u2013664 (2021).","journal-title":"Nat. Metab."},{"key":"1513_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/pr.118.015735","volume":"72","author":"T Schumann","year":"2020","unstructured":"Schumann, T. et al. Solute carrier transporters as potential targets for the treatment of metabolic disease. Pharmacol. Rev. 72, 343\u2013379 (2020).","journal-title":"Pharmacol. Rev."},{"key":"1513_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2025.04.25.650669","author":"R Nayak","year":"2025","unstructured":"Nayak, R. et al. Dysregulation of multiple solute carrier genes and metabolic deficits in SLC1A4-mutant human iPSC-derived hippocampal neurons. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.04.25.650669 (2025).","journal-title":"bioRxiv"},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ajhg.2015.02.016","volume":"96","author":"GL Carvill","year":"2015","unstructured":"Carvill, G. L. et al. Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am. J. Hum. Genet. 96, 808\u2013815 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"1513_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep30072","volume":"6","author":"H Saitsu","year":"2016","unstructured":"Saitsu, H. et al. Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Sci. Rep. 6, 30072 (2016).","journal-title":"Sci. Rep."},{"key":"1513_CR18","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1093\/brain\/awv263","volume":"138","author":"K Hardies","year":"2015","unstructured":"Hardies, K. et al. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Brain 138, 3238\u20133250 (2015).","journal-title":"Brain"},{"key":"1513_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/2040-2392-4-36","volume":"4","author":"BS Abrahams","year":"2013","unstructured":"Abrahams, B. S. et al. SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol. Autism 4, 36 (2013).","journal-title":"Mol. Autism"},{"key":"1513_CR20","doi-asserted-by":"publisher","first-page":"102599","DOI":"10.1016\/j.arr.2024.102599","volume":"104","author":"HK Krishnamurthy","year":"2025","unstructured":"Krishnamurthy, H. K. et al. An overview of the genes and biomarkers in Alzheimer\u2019s disease. Ageing Res. Rev. 104, 102599 (2025).","journal-title":"Ageing Res. Rev."},{"key":"1513_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41380-021-01341-5","volume":"27","author":"MEA Reith","year":"2022","unstructured":"Reith, M. E. A. et al. The dopamine transporter gene SLC6A3: multidisease risks. Mol. Psychiatry 27, 1031\u20131046 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1513_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin, A. et al. Membrane transporters in drug development and as determinants of precision medicine. Nat. Rev. Drug Discov. 23, 255\u2013280 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff, A. N. et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol. Int. 13, 387\u2013401 (2021).","journal-title":"Neurol. Int."},{"key":"1513_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4626","volume":"14","author":"L Lin","year":"2015","unstructured":"Lin, L., Yee, S. W., Kim, R. B. & Giacomini, K. M. SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug Discov. 14, 543\u2013560 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte, H. H. & Freissmuth, M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol. Sci. 36, 41\u201350 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"1513_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1471-4159.2009.05982.x","volume":"109","author":"KK Madsen","year":"2009","unstructured":"Madsen, K. K. et al. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J. Neurochem. 109, 139\u2013144 (2009).","journal-title":"J. Neurochem."},{"key":"1513_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41422-023-00906-z","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines. Cell Res. 34, 47\u201357 (2024).","journal-title":"Cell Res."},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/epi.13340","volume":"57","author":"H Klitgaard","year":"2016","unstructured":"Klitgaard, H. et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 57, 538\u2013548 (2016).","journal-title":"Epilepsia"},{"key":"1513_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47322-4","volume":"15","author":"A Yamagata","year":"2024","unstructured":"Yamagata, A. et al. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A. Nat. Commun. 15, 3027 (2024).","journal-title":"Nat. Commun."},{"key":"1513_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2024.02.026","volume":"187","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Transport mechanism and pharmacology of the human GlyT1. Cell 187, 1719\u20131732 (2024).","journal-title":"Cell"},{"key":"1513_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nrd3893","volume":"12","author":"RJ Harvey","year":"2013","unstructured":"Harvey, R. J. & Yee, B. K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat. Rev. Drug Discov. 12, 866\u2013885 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/d41573-020-00056-6","volume":"19","author":"G Superti-Furga","year":"2020","unstructured":"Superti-Furga, G. et al. The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nat. Rev. Drug Discov. 19, 429\u2013430 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cell.2015.07.022","volume":"162","author":"A C\u00e9sar-Razquin","year":"2015","unstructured":"C\u00e9sar-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478\u2013487 (2015).","journal-title":"Cell"},{"key":"1513_CR34","doi-asserted-by":"publisher","first-page":"722889","DOI":"10.3389\/fphar.2021.722889","volume":"12","author":"V Dvorak","year":"2021","unstructured":"Dvorak, V. et al. An overview of cell-based assay platforms for the solute carrier family of transporters. Front. Pharmacol. 12, 722889 (2021).","journal-title":"Front. Pharmacol."},{"key":"1513_CR35","doi-asserted-by":"publisher","first-page":"110616","DOI":"10.1016\/j.celrep.2022.110616","volume":"39","author":"RA Phillips","year":"2022","unstructured":"Phillips, R. A. et al. An atlas of transcriptionally defined cell populations in the rat ventral tegmental area. Cell Rep. 39, 110616 (2022).","journal-title":"Cell Rep."},{"key":"1513_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mam.2012.07.005","volume":"34","author":"HO Lawal","year":"2013","unstructured":"Lawal, H. O. & Krantz, D. E. SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol. Asp. Med. 34, 360\u2013372 (2013).","journal-title":"Mol. Asp. Med."},{"key":"1513_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14198-8","volume":"11","author":"MY Batiuk","year":"2020","unstructured":"Batiuk, M. Y. et al. Identification of region-specific astrocyte subtypes at single cell resolution. Nat. Commun. 11, 1220 (2020).","journal-title":"Nat. Commun."},{"key":"1513_CR38","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","volume":"138","author":"L Schaller","year":"2019","unstructured":"Schaller, L. & Lauschke, V. M. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum. Genet. 138, 1359\u20131377 (2019).","journal-title":"Hum. Genet."},{"key":"1513_CR39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ana.25477","volume":"85","author":"AB Stergachis","year":"2019","unstructured":"Stergachis, A. B. et al. Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism. Ann. Neurol. 85, 921\u2013926 (2019).","journal-title":"Ann. Neurol."},{"key":"1513_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","volume":"81","author":"A Doble","year":"1999","unstructured":"Doble, A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163\u2013221 (1999).","journal-title":"Pharmacol. Ther."},{"key":"1513_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38120-5","volume":"14","author":"B Qiu","year":"2023","unstructured":"Qiu, B. & Boudker, O. Symport and antiport mechanisms of human glutamate transporters. Nat. Commun. 14, 2579 (2023).","journal-title":"Nat. Commun."},{"key":"1513_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15811","volume":"166","author":"JV Andersen","year":"2023","unstructured":"Andersen, J. V. & Schousboe, A. Milestone review: metabolic dynamics of glutamate and GABA mediated neurotransmission \u2014 the essential roles of astrocytes. J. Neurochem. 166, 109\u2013137 (2023).","journal-title":"J. Neurochem."},{"key":"1513_CR43","doi-asserted-by":"publisher","first-page":"103474","DOI":"10.1016\/j.ebiom.2021.103474","volume":"69","author":"A Oyarz\u00e1bal","year":"2021","unstructured":"Oyarz\u00e1bal, A., Musokhranova, U., Barros, Lf. & Garc\u00eda-Cazorla, A. Energy metabolism in childhood neurodevelopmental disorders. EBioMedicine 69, 103474 (2021).","journal-title":"EBioMedicine"},{"key":"1513_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nature13185","volume":"508","author":"JA Miller","year":"2014","unstructured":"Miller, J. A. et al. Transcriptional landscape of the prenatal human brain. Nature 508, 199\u2013206 (2014).","journal-title":"Nature"},{"key":"1513_CR45","first-page":"4259","volume":"148","author":"D Lai","year":"2025","unstructured":"Lai, D. et al. SLC35A2 loss-of-function variants affect glycomic signatures, neuronal fate and network dynamics. Brain 148, 4259\u20134274 (2025).","journal-title":"Brain"},{"key":"1513_CR46","doi-asserted-by":"publisher","first-page":"15886","DOI":"10.1523\/JNEUROSCI.4505-11.2012","volume":"32","author":"H He","year":"2012","unstructured":"He, H. et al. Neurodevelopmental role for VGLUT2 in pyramidal neuron plasticity, dendritic refinement, and in spatial learning. J. Neurosci. 32, 15886\u201315901 (2012).","journal-title":"J. Neurosci."},{"key":"1513_CR47","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.cell.2023.03.027","volume":"186","author":"F Oury","year":"2023","unstructured":"Oury, F. & Pierani, A. Transient perinatal metabolic shifts determine neuronal survival and functional circuit formation. Cell 186, 1819\u20131821 (2023).","journal-title":"Cell"},{"key":"1513_CR48","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cell.2016.11.013","volume":"167","author":"DC T\u0103rlungeanu","year":"2016","unstructured":"T\u0103rlungeanu, D. C. et al. Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder. Cell 167, 1481\u20131494 (2016).","journal-title":"Cell"},{"key":"1513_CR49","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cell.2023.02.037","volume":"186","author":"LS Knaus","year":"2023","unstructured":"Knaus, L. S. et al. Large neutral amino acid levels tune perinatal neuronal excitability and survival. Cell 186, 1950\u20131967 (2023).","journal-title":"Cell"},{"key":"1513_CR50","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1111\/epi.17352","volume":"63","author":"L Gracie","year":"2022","unstructured":"Gracie, L., Rostami-Hochaghan, D., Taweel, B. & Mirza, N. SAGAS Scientists\u2019 Collaborative The Seizure-Associated Genes Across Species (SAGAS) database offers insights into epilepsy genes, pathways and treatments. Epilepsia 63, 2403\u20132412 (2022).","journal-title":"Epilepsia"},{"key":"1513_CR51","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.neuron.2022.03.008","volume":"110","author":"JS Sadick","year":"2022","unstructured":"Sadick, J. S. et al. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer\u2019s disease. Neuron 110, 1788\u20131805 (2022).","journal-title":"Neuron"},{"key":"1513_CR52","doi-asserted-by":"publisher","first-page":"eabm6131","DOI":"10.1126\/science.abm6131","volume":"385","author":"PS Minhas","year":"2024","unstructured":"Minhas, P. S. et al. Restoring hippocampal glucose metabolism rescues cognition across Alzheimer\u2019s disease pathologies. Science 385, eabm6131 (2024).","journal-title":"Science"},{"key":"1513_CR53","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.cmet.2018.05.011","volume":"27","author":"MP Mattson","year":"2018","unstructured":"Mattson, M. P. & Arumugam, T. V. Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab. 27, 1176\u20131199 (2018).","journal-title":"Cell Metab."},{"key":"1513_CR54","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1021\/acs.jproteome.5b01020","volume":"15","author":"G Paglia","year":"2016","unstructured":"Paglia, G. et al. Unbiased metabolomic investigation of Alzheimer\u2019s disease brain points to dysregulation of mitochondrial aspartate metabolism. J. Proteome Res. 15, 608\u2013618 (2016).","journal-title":"J. Proteome Res."},{"key":"1513_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/jpet.112.192138","volume":"342","author":"A Johri","year":"2012","unstructured":"Johri, A. & Beal, M. F. Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342, 619\u2013630 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1513_CR56","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nchembio.497","volume":"7","author":"BC Dickinson","year":"2011","unstructured":"Dickinson, B. C., Peltier, J., Stone, D., Schaffer, D. V. & Chang, C. J. Nox2 redox signaling maintains essential cell populations in the brain. Nat. Chem. Biol. 7, 106\u2013112 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"1513_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.7901908","volume":"262","author":"JT Coyle","year":"1993","unstructured":"Coyle, J. T. & Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689\u2013695 (1993).","journal-title":"Science"},{"key":"1513_CR58","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias, V., Junn, E. & Mouradian, M. M. The role of oxidative stress in Parkinson\u2019s disease. J. Parkinsons Dis. 3, 461\u2013491 (2013).","journal-title":"J. Parkinsons Dis."},{"key":"1513_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.molmed.2022.02.003","volume":"28","author":"Z-L Wang","year":"2022","unstructured":"Wang, Z.-L., Yuan, L., Li, W. & Li, J.-Y. Ferroptosis in Parkinson\u2019s disease: glia-neuron crosstalk. Trends Mol. Med. 28, 258\u2013269 (2022).","journal-title":"Trends Mol. Med."},{"key":"1513_CR60","doi-asserted-by":"publisher","first-page":"102077","DOI":"10.1016\/j.arr.2023.102077","volume":"91","author":"X-S Ding","year":"2023","unstructured":"Ding, X.-S. et al. Ferroptosis in Parkinson\u2019s disease: molecular mechanisms and therapeutic potential. Ageing Res. Rev. 91, 102077 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1513_CR61","doi-asserted-by":"publisher","first-page":"101716","DOI":"10.1016\/j.pneurobio.2019.101716","volume":"184","author":"PJ Derry","year":"2020","unstructured":"Derry, P. J. et al. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer\u2019s disease from a ferroptosis perspective. Prog. Neurobiol. 184, 101716 (2020).","journal-title":"Prog. Neurobiol."},{"key":"1513_CR62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.expneurol.2014.06.023","volume":"261","author":"EL Unger","year":"2014","unstructured":"Unger, E. L., Bianco, L. E., Jones, B. C., Allen, R. P. & Earley, C. J. Low brain iron effects and reversibility on striatal dopamine dynamics. Exp. Neurol. 261, 462\u2013468 (2014).","journal-title":"Exp. Neurol."},{"key":"1513_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.neuropharm.2018.03.015","volume":"135","author":"Y Hirata","year":"2018","unstructured":"Hirata, Y. et al. Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22 cells. Neuropharmacology 135, 242\u2013252 (2018).","journal-title":"Neuropharmacology"},{"key":"1513_CR64","doi-asserted-by":"publisher","first-page":"101089","DOI":"10.1016\/j.redox.2018.101089","volume":"21","author":"W Fischer","year":"2019","unstructured":"Fischer, W., Currais, A., Liang, Z., Pinto, A. & Maher, P. Old age-associated phenotypic screening for Alzheimer\u2019s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa. Redox Biol. 21, 101089 (2019).","journal-title":"Redox Biol."},{"key":"1513_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida, A. et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci. Rep. 7, 1398 (2017).","journal-title":"Sci. Rep."},{"key":"1513_CR66","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.tem.2024.04.015","volume":"35","author":"MR Teh","year":"2024","unstructured":"Teh, M. R., Armitage, A. E. & Drakesmith, H. Why cells need iron: a compendium of iron utilisation. Trends Endocrinol. Metab. 35, 1026\u20131049 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"1513_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/mol.112.083428","volume":"83","author":"E Fung","year":"2013","unstructured":"Fung, E. et al. High-throughput screening of small molecules identifies hepcidin antagonists. Mol. Pharmacol. 83, 681\u2013690 (2013).","journal-title":"Mol. Pharmacol."},{"key":"1513_CR68","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1021\/acschemneuro.3c00717","volume":"14","author":"D Shukla","year":"2023","unstructured":"Shukla, D. et al. Glutathione depletion and concomitant elevation of susceptibility in patients with Parkinson\u2019s disease: state-of-the-art MR spectroscopy and neuropsychological study. ACS Chem. Neurosci. 14, 4383\u20134394 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"1513_CR69","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3233\/JAD-132483","volume":"40","author":"S Saharan","year":"2014","unstructured":"Saharan, S. & Mandal, P. K. The emerging role of glutathione in Alzheimer\u2019s disease. J. Alzheimers Dis. 40, 519\u2013529 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"1513_CR70","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1073\/pnas.1722677115","volume":"115","author":"E Kaplan","year":"2018","unstructured":"Kaplan, E. et al. ASCT1 (Slc1a4) transporter is a physiologic regulator of brain d-serine and neurodevelopment. Proc. Natl Acad. Sci. USA 115, 9628\u20139633 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1513_CR71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-021-04025-w","volume":"599","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells. Nature 599, 136\u2013140 (2021).","journal-title":"Nature"},{"key":"1513_CR72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13024-021-00455-2","volume":"16","author":"A Gialluisi","year":"2021","unstructured":"Gialluisi, A. et al. Identification of sixteen novel candidate genes for late onset Parkinson\u2019s disease. Mol. Neurodegener. 16, 35 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1513_CR73","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nm1772","volume":"14","author":"NE Savaskan","year":"2008","unstructured":"Savaskan, N. E. et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14, 629\u2013632 (2008).","journal-title":"Nat. Med."},{"key":"1513_CR74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/jnc.13405","volume":"136","author":"I Miyazaki","year":"2016","unstructured":"Miyazaki, I., Murakami, S., Torigoe, N., Kitamura, Y. & Asanuma, M. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J. Neurochem. 136, 194\u2013204 (2016).","journal-title":"J. Neurochem."},{"key":"1513_CR75","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41386-024-01914-2","volume":"49","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants. Neuropsychopharmacology 49, 1783\u20131791 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1513_CR76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1471-4159.2001.00451.x","volume":"78","author":"CM Lauderback","year":"2001","unstructured":"Lauderback, C. M. et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer\u2019s disease brain: the role of Abeta1-42. J. Neurochem. 78, 413\u2013416 (2001).","journal-title":"J. Neurochem."},{"key":"1513_CR77","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41586-024-07606-7","volume":"632","author":"H Mathys","year":"2024","unstructured":"Mathys, H. et al. Single-cell multiregion dissection of Alzheimer\u2019s disease. Nature 632, 858\u2013868 (2024).","journal-title":"Nature"},{"key":"1513_CR78","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smaji\u0107","year":"2022","unstructured":"Smaji\u0107, S. et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145, 964\u2013978 (2022).","journal-title":"Brain"},{"key":"1513_CR79","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12035-016-0293-5","volume":"55","author":"S Singh","year":"2018","unstructured":"Singh, S., Mishra, A., Srivastava, N., Shukla, R. & Shukla, S. Acetyl-l-carnitine via upegulating dopamine D1 receptor and attenuating microglial activation prevents neuronal loss and improves memory functions in parkinsonian rats. Mol. Neurobiol. 55, 583\u2013602 (2018).","journal-title":"Mol. Neurobiol."},{"key":"1513_CR80","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.chembiol.2023.06.018","volume":"30","author":"P-T Doulias","year":"2023","unstructured":"Doulias, P.-T. et al. S-Nitrosylation-mediated dysfunction of TCA cycle enzymes in synucleinopathy studied in postmortem human brains and hiPSC-derived neurons. Cell Chem. Biol. 30, 965\u2013975 (2023).","journal-title":"Cell Chem. Biol."},{"key":"1513_CR81","doi-asserted-by":"publisher","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","volume":"4","author":"O Cooper","year":"2012","unstructured":"Cooper, O. et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease. Sci. Transl Med. 4, 141ra90 (2012).","journal-title":"Sci. Transl Med."},{"key":"1513_CR82","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41580-024-00820-1","volume":"26","author":"B Cartes-Saavedra","year":"2025","unstructured":"Cartes-Saavedra, B., Ghosh, A. & Hajn\u00f3czky, G. The roles of mitochondria in global and local intracellular calcium signalling. Nat. Rev. Mol. Cell Biol. 26, 456\u2013475 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1513_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16074-2","volume":"11","author":"M Calvo-Rodriguez","year":"2020","unstructured":"Calvo-Rodriguez, M. et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer\u2019s disease. Nat. Commun. 11, 2146 (2020).","journal-title":"Nat. Commun."},{"key":"1513_CR84","doi-asserted-by":"publisher","first-page":"111280","DOI":"10.1016\/j.celrep.2022.111280","volume":"40","author":"D Shah","year":"2022","unstructured":"Shah, D. et al. Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer\u2019s disease. Cell Rep. 40, 111280 (2022).","journal-title":"Cell Rep."},{"key":"1513_CR85","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1042\/BST20230012","volume":"51","author":"SH Lee","year":"2023","unstructured":"Lee, S. H., Duron, H. E. & Chaudhuri, D. Beyond the TCA cycle: new insights into mitochondrial calcium regulation of oxidative phosphorylation. Biochem. Soc. Trans. 51, 1661\u20131673 (2023).","journal-title":"Biochem. Soc. Trans."},{"key":"1513_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11813-6","volume":"10","author":"P Jadiya","year":"2019","unstructured":"Jadiya, P. et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer\u2019s disease. Nat. Commun. 10, 3885 (2019).","journal-title":"Nat. Commun."},{"key":"1513_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/alz.046328","volume":"16","author":"FJ Castora","year":"2020","unstructured":"Castora, F. J. et al. Altered expression of mitochondrial genes involved in energy production and mitochondrial biogenesis is related to an increase in inflammatory factors associated with Alzheimer\u2019s disease. Alzheimers Dement. 16, e046328 (2020).","journal-title":"Alzheimers Dement."},{"key":"1513_CR88","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1091\/mbc.e13-08-0502","volume":"25","author":"NE Hoffman","year":"2014","unstructured":"Hoffman, N. E. et al. SLC25A23 augments mitochondrial Ca2+ uptake, interacts with MCU, and induces oxidative stress-mediated cell death. Mol. Biol. Cell 25, 936\u2013947 (2014).","journal-title":"Mol. Biol. Cell"},{"key":"1513_CR89","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64821","volume":"10","author":"CM D\u00edaz-Garc\u00eda","year":"2021","unstructured":"D\u00edaz-Garc\u00eda, C. M. et al. The distinct roles of calcium in rapid control of neuronal glycolysis and the tricarboxylic acid cycle. eLife 10, e64821 (2021).","journal-title":"eLife"},{"key":"1513_CR90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.51.1.125","volume":"51","author":"K Ishii","year":"1998","unstructured":"Ishii, K. et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer\u2019s disease. Neurology 51, 125\u2013130 (1998).","journal-title":"Neurology"},{"key":"1513_CR91","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s42003-020-1079-x","volume":"3","author":"TC Hammond","year":"2020","unstructured":"Hammond, T. C. et al. \u03b2-Amyloid and tau drive early Alzheimer\u2019s disease decline while glucose hypometabolism drives late decline. Commun. Biol. 3, 352 (2020).","journal-title":"Commun. Biol."},{"key":"1513_CR92","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.nicl.2018.11.004","volume":"21","author":"F Albrecht","year":"2019","unstructured":"Albrecht, F., Ballarini, T., Neumann, J. & Schroeter, M. L. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson\u2019s disease: a whole-brain multimodal imaging meta-analysis. Neuroimage Clin. 21, 101594 (2019).","journal-title":"Neuroimage Clin."},{"key":"1513_CR93","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","volume":"32","author":"L Mosconi","year":"2005","unstructured":"Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer\u2019s disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486\u2013510 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1513_CR94","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.brainresbull.2023.110672","volume":"199","author":"C Dai","year":"2023","unstructured":"Dai, C. et al. Glucose metabolism impairment in Parkinson\u2019s disease. Brain Res. Bull. 199, 110672 (2023).","journal-title":"Brain Res. Bull."},{"key":"1513_CR95","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/molecules27030951","volume":"27","author":"DA Butterfield","year":"2022","unstructured":"Butterfield, D. A. et al. Metabolic features of brain function with relevance to clinical features of Alzheimer and Parkinson diseases. Molecules 27, 951 (2022).","journal-title":"Molecules"},{"key":"1513_CR96","doi-asserted-by":"publisher","first-page":"eabe5640","DOI":"10.1126\/scitranslmed.abe5640","volume":"13","author":"X Xiang","year":"2021","unstructured":"Xiang, X. et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci. Transl Med. 13, eabe5640 (2021).","journal-title":"Sci. Transl Med."},{"key":"1513_CR97","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487 (2017).","journal-title":"Nature"},{"key":"1513_CR98","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","volume":"26","author":"ECB Johnson","year":"2020","unstructured":"Johnson, E. C. B. et al. Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26, 769\u2013780 (2020).","journal-title":"Nat. Med."},{"key":"1513_CR99","doi-asserted-by":"publisher","first-page":"eadp1115","DOI":"10.1126\/sciadv.adp1115","volume":"10","author":"CG Ardanaz","year":"2024","unstructured":"Ardanaz, C. G. et al. Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis. Sci. Adv. 10, eadp1115 (2024).","journal-title":"Sci. Adv."},{"key":"1513_CR100","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/alz.12310","volume":"17","author":"ER Saito","year":"2021","unstructured":"Saito, E. R. et al. Alzheimer\u2019s disease alters oligodendrocytic glycolytic and ketolytic gene expression. Alzheimers Dement. 17, 1474\u20131486 (2021).","journal-title":"Alzheimers Dement."},{"key":"1513_CR101","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nn.3966","volume":"18","author":"EA Winkler","year":"2015","unstructured":"Winkler, E. A. et al. GLUT1 reductions exacerbate Alzheimer\u2019s disease vasculo-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521\u2013530 (2015).","journal-title":"Nat. Neurosci."},{"key":"1513_CR102","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.febslet.2007.12.035","volume":"582","author":"Y Liu","year":"2008","unstructured":"Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I. & Gong, C.-X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett. 582, 359\u2013364 (2008).","journal-title":"FEBS Lett."},{"key":"1513_CR103","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/acn3.530","volume":"5","author":"R Mullins","year":"2018","unstructured":"Mullins, R., Reiter, D. & Kapogiannis, D. Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer\u2019s brain. Ann. Clin. Transl. Neurol. 5, 262\u2013272 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1513_CR104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154595","volume":"7","author":"C He","year":"2022","unstructured":"He, C. et al. Recurrent moderate hypoglycemia accelerates the progression of Alzheimer\u2019s disease through impairment of the TRPC6\/GLUT3 pathway. JCI Insight 7, e154595 (2022).","journal-title":"JCI Insight"},{"key":"1513_CR105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11064-016-2099-2","volume":"42","author":"LB Achanta","year":"2017","unstructured":"Achanta, L. B. & Rae, C. D. \u03b2-Hydroxybutyrate in the brain: one molecule, multiple mechanisms. Neurochem. Res. 42, 35\u201349 (2017).","journal-title":"Neurochem. Res."},{"key":"1513_CR106","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/brain\/awq203","volume":"133","author":"N Villain","year":"2010","unstructured":"Villain, N. et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer\u2019s disease. Brain 133, 3301\u20133314 (2010).","journal-title":"Brain"},{"key":"1513_CR107","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao, C., Jiang, J., Tan, Y. & Chen, S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal. Transduct. Target. Ther. 8, 359 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1513_CR108","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/biom14030289","volume":"14","author":"K Stoklund Dittlau","year":"2024","unstructured":"Stoklund Dittlau, K. & Freude, K. Astrocytes: the stars in neurodegeneration? Biomolecules 14, 289 (2024).","journal-title":"Biomolecules"},{"key":"1513_CR109","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41593-020-00735-y","volume":"23","author":"H Chun","year":"2020","unstructured":"Chun, H. et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer\u2019s disease via H2O2- production. Nat. Neurosci. 23, 1555\u20131566 (2020).","journal-title":"Nat. Neurosci."},{"key":"1513_CR110","doi-asserted-by":"publisher","first-page":"107017","DOI":"10.1016\/j.parkreldis.2024.107017","volume":"124","author":"M Scholefield","year":"2024","unstructured":"Scholefield, M. et al. Human dementia with Lewy bodies brain shows widespread urea elevations. Parkinsonism Relat. Disord. 124, 107017 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1513_CR111","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/ijms21031133","volume":"21","author":"B Polis","year":"2020","unstructured":"Polis, B. et al. Arginase inhibition supports survival and differentiation of neuronal precursors in adult Alzheimer\u2019s disease mice. Int. J. Mol. Sci. 21, 1133 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1513_CR112","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/10738584211069060","volume":"29","author":"V Gkini","year":"2023","unstructured":"Gkini, V. & Namba, T. Glutaminolysis and the control of neural progenitors in neocortical development and evolution. Neuroscientist 29, 177\u2013189 (2023).","journal-title":"Neuroscientist"},{"key":"1513_CR113","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s11064-021-03283-4","volume":"46","author":"AC Jones","year":"2021","unstructured":"Jones, A. C., Pinki, F., Stewart, G. S. & Costello, D. A. Inhibition of urea transporter (UT)-B modulates LPS-induced inflammatory responses in BV2 microglia and N2a neuroblastoma cells. Neurochem. Res. 46, 1322\u20131329 (2021).","journal-title":"Neurochem. Res."},{"key":"1513_CR114","doi-asserted-by":"publisher","first-page":"100646","DOI":"10.1016\/j.bbih.2023.100646","volume":"30","author":"M Gevezova","year":"2023","unstructured":"Gevezova, M. et al. Autistic spectrum disorder (ASD) \u2014 gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment. Brain Behav. Immun. Health 30, 100646 (2023).","journal-title":"Brain Behav. Immun. Health"},{"key":"1513_CR115","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s11064-017-2261-5","volume":"42","author":"JE Sperringer","year":"2017","unstructured":"Sperringer, J. E., Addington, A. & Hutson, S. M. Branched-chain amino acids and brain metabolism. Neurochem. Res. 42, 1697\u20131709 (2017).","journal-title":"Neurochem. Res."},{"key":"1513_CR116","doi-asserted-by":"publisher","first-page":"1539S","DOI":"10.1093\/jn\/135.6.1539S","volume":"135","author":"JD Fernstrom","year":"2005","unstructured":"Fernstrom, J. D. Branched-chain amino acids and brain function. J. Nutr. 135, 1539S\u20131546SS (2005).","journal-title":"J. Nutr."},{"key":"1513_CR117","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41380-024-02725-z","volume":"30","author":"I Khaliulin","year":"2025","unstructured":"Khaliulin, I., Hamoudi, W. & Amal, H. The multifaceted role of mitochondria in autism spectrum disorder. Mol. Psychiatry 30, 629\u2013650 (2025).","journal-title":"Mol. Psychiatry"},{"key":"1513_CR118","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.mp.4002120","volume":"13","author":"AM Lepagnol-Bestel","year":"2008","unstructured":"Lepagnol-Bestel, A. M. et al. SLC25A12 expression is associated with neurite outgrowth and is upregulated in the prefrontal cortex of autistic subjects. Mol. Psychiatry 13, 385\u2013397 (2008).","journal-title":"Mol. Psychiatry"},{"key":"1513_CR119","doi-asserted-by":"publisher","first-page":"10625","DOI":"10.1073\/pnas.91.22.10625","volume":"91","author":"L Pellerin","year":"1994","unstructured":"Pellerin, L. & Magistretti, P. J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl Acad. Sci. USA 91, 10625\u201310629 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1513_CR120","doi-asserted-by":"publisher","first-page":"RP100747","DOI":"10.7554\/eLife.100747.3","volume":"13","author":"MT Goswami","year":"2025","unstructured":"Goswami, M. T. et al. Glutamine catabolism supports amino acid biosynthesis and suppresses the integrated stress response to promote photoreceptor survival. eLife 13, RP100747 (2025).","journal-title":"eLife"},{"key":"1513_CR121","doi-asserted-by":"publisher","first-page":"108719","DOI":"10.1016\/j.neuropharm.2021.108719","volume":"196","author":"JV Andersen","year":"2021","unstructured":"Andersen, J. V. et al. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology 196, 108719 (2021).","journal-title":"Neuropharmacology"},{"key":"1513_CR122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jpsychires.2016.02.016","volume":"77","author":"ND Merner","year":"2016","unstructured":"Merner, N. D. et al. Gain-of-function missense variant in SLC12A2, encoding the bumetanide-sensitive NKCC1 cotransporter, identified in human schizophrenia. J. Psychiatr. Res. 77, 22\u201326 (2016).","journal-title":"J. Psychiatr. Res."},{"key":"1513_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406928121","volume":"121","author":"SK Godavarthi","year":"2024","unstructured":"Godavarthi, S. K., Li, H.-Q., Pratelli, M. & Spitzer, N. C. Embryonic exposure to environmental factors drives transmitter switching in the neonatal mouse cortex causing autistic-like adult behavior. Proc. Natl Acad. Sci. USA 121, e2406928121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1513_CR124","doi-asserted-by":"publisher","first-page":"fcaa170","DOI":"10.1093\/braincomms\/fcaa170","volume":"2","author":"K Goodspeed","year":"2020","unstructured":"Goodspeed, K. et al. Current knowledge of SLC6A1-related neurodevelopmental disorders. Brain Commun. 2, fcaa170 (2020).","journal-title":"Brain Commun."},{"key":"1513_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-020-00612-6","volume":"13","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism. Mol. Brain 13, 76 (2020).","journal-title":"Mol. Brain"},{"key":"1513_CR126","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/brain\/awab207","volume":"144","author":"F Mermer","year":"2021","unstructured":"Mermer, F. et al. Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. Brain 144, 2499\u20132512 (2021).","journal-title":"Brain"},{"key":"1513_CR127","doi-asserted-by":"publisher","first-page":"108910","DOI":"10.1016\/j.neuropharm.2021.108910","volume":"205","author":"W L\u00f6scher","year":"2022","unstructured":"L\u00f6scher, W. & Kaila, K. CNS pharmacology of NKCC1 inhibitors. Neuropharmacology 205, 108910 (2022).","journal-title":"Neuropharmacology"},{"key":"1513_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsptsci.2c00197","volume":"6","author":"A Savardi","year":"2023","unstructured":"Savardi, A., Patricelli Malizia, A., De Vivo, M., Cancedda, L. & Borgogno, M. Preclinical development of the Na-K-2Cl co-transporter-1 (NKCC1) inhibitor ARN23746 for the treatment of neurodevelopmental disorders. ACS Pharmacol. Transl Sci. 6, 1\u201311 (2023).","journal-title":"ACS Pharmacol. Transl Sci."},{"key":"1513_CR129","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/mp.2013.102","volume":"18","author":"PJ Hamilton","year":"2013","unstructured":"Hamilton, P. J. et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol. Psychiatry 18, 1315\u20131323 (2013).","journal-title":"Mol. Psychiatry"},{"key":"1513_CR130","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1074\/jbc.RA118.001753","volume":"293","author":"F Herborg","year":"2018","unstructured":"Herborg, F., Andreassen, T. F., Berlin, F., Loland, C. J. & Gether, U. Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes. J. Biol. Chem. 293, 7250\u20137262 (2018).","journal-title":"J. Biol. Chem."},{"key":"1513_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.90","volume":"4","author":"E Bowton","year":"2014","unstructured":"Bowton, E. et al. SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatry 4, e464 (2014).","journal-title":"Transl Psychiatry"},{"key":"1513_CR132","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1172\/JCI127411","volume":"129","author":"GE DiCarlo","year":"2019","unstructured":"DiCarlo, G. E. et al. Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. J. Clin. Invest. 129, 3407\u20133419 (2019).","journal-title":"J. Clin. Invest."},{"key":"1513_CR133","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021946","volume":"99","author":"W Wongpaiboonwattana","year":"2020","unstructured":"Wongpaiboonwattana, W., Plong-On, O., Hnoonual, A. & Limprasert, P. Significant associations between 5-hydroxytryptaminetransporter-linked promoter region polymorphisms of the serotonin transporter (solute carrier family 6 member 4) gene and Thai patients with autism spectrum disorder. Medicine 99, e21946 (2020).","journal-title":"Medicine"},{"key":"1513_CR134","first-page":"CD004677","volume":"2013","author":"K Williams","year":"2013","unstructured":"Williams, K., Brignell, A., Randall, M., Silove, N. & Hazell, P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst. Rev. 2013, CD004677 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1513_CR135","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/aur.1317","volume":"6","author":"A Oblak","year":"2013","unstructured":"Oblak, A., Gibbs, T. T. & Blatt, G. J. Reduced serotonin receptor subtypes in a limbic and a neocortical region in autism. Autism Res. 6, 571\u2013583 (2013).","journal-title":"Autism Res."},{"key":"1513_CR136","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82641","volume":"12","author":"S Bhat","year":"2023","unstructured":"Bhat, S. et al. A mechanism of uncompetitive inhibition of the serotonin transporter. eLife 12, e82641 (2023).","journal-title":"eLife"},{"key":"1513_CR137","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neuroscience.2015.11.010","volume":"321","author":"CL Muller","year":"2016","unstructured":"Muller, C. L., Anacker, A. M. J. & Veenstra-VanderWeele, J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience 321, 24\u201341 (2016).","journal-title":"Neuroscience"},{"key":"1513_CR138","doi-asserted-by":"publisher","first-page":"114298","DOI":"10.1016\/j.expneurol.2022.114298","volume":"361","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. Auts2 regulated autism-like behavior, glucose metabolism and oxidative stress in mice. Exp. Neurol. 361, 114298 (2023).","journal-title":"Exp. Neurol."},{"key":"1513_CR139","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fnmol.2017.00034","volume":"10","author":"N Cheng","year":"2017","unstructured":"Cheng, N., Rho, J. M. & Masino, S. A. Metabolic dysfunction underlying autism spectrum disorder and potential treatment approaches. Front. Mol. Neurosci. 10, 34 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"1513_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/2040-2392-3-12","volume":"3","author":"A Anitha","year":"2012","unstructured":"Anitha, A. et al. Brain region-specific altered expression and association of mitochondria-related genes in autism. Mol. Autism 3, 12 (2012).","journal-title":"Mol. Autism"},{"key":"1513_CR141","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ana.20062","volume":"55","author":"PG Sullivan","year":"2004","unstructured":"Sullivan, P. G. et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55, 576\u2013580 (2004).","journal-title":"Ann. Neurol."},{"key":"1513_CR142","doi-asserted-by":"publisher","first-page":"37391","DOI":"10.1074\/jbc.M605552200","volume":"281","author":"SL Chan","year":"2006","unstructured":"Chan, S. L. et al. Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells. J. Biol. Chem. 281, 37391\u201337403 (2006).","journal-title":"J. Biol. Chem."},{"key":"1513_CR143","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1126\/science.aav8130","volume":"364","author":"D Velmeshev","year":"2019","unstructured":"Velmeshev, D. et al. Single-cell genomics identifies cell type-specific molecular changes in autism. Science 364, 685\u2013689 (2019).","journal-title":"Science"},{"key":"1513_CR144","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-020-00189-z","volume":"9","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Current understanding of metal ions in the pathogenesis of Alzheimer\u2019s disease. Transl Neurodegener. 9, 10 (2020).","journal-title":"Transl Neurodegener."},{"key":"1513_CR145","doi-asserted-by":"publisher","first-page":"118826","DOI":"10.1016\/j.lfs.2020.118826","volume":"265","author":"E Akyuz","year":"2021","unstructured":"Akyuz, E. et al. Revisiting the role of neurotransmitters in epilepsy: an updated review. Life Sci. 265, 118826 (2021).","journal-title":"Life Sci."},{"key":"1513_CR146","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41582-022-00651-8","volume":"18","author":"JM Rho","year":"2022","unstructured":"Rho, J. M. & Boison, D. The metabolic basis of epilepsy. Nat. Rev. Neurol. 18, 333\u2013347 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR147","doi-asserted-by":"publisher","first-page":"864514","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi, R., Arjmand, S., B\u00e6rentzen, S. L., Gjedde, A. & Landau, A. M. Synaptic vesicle glycoprotein 2A: features and functions. Front. Neurosci. 16, 864514 (2022).","journal-title":"Front. Neurosci."},{"key":"1513_CR148","doi-asserted-by":"publisher","first-page":"7075","DOI":"10.1074\/jbc.RA120.012614","volume":"295","author":"A Ilie","year":"2020","unstructured":"Ilie, A. et al. Assorted dysfunctions of endosomal alkali cation\/proton exchanger SLC9A6 variants linked to Christianson syndrome. J. Biol. Chem. 295, 7075\u20137095 (2020).","journal-title":"J. Biol. Chem."},{"key":"1513_CR149","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/19336950.2016.1207024","volume":"10","author":"I Rubio-Aliaga","year":"2016","unstructured":"Rubio-Aliaga, I. & Wagner, C. A. Regulation and function of the SLC38A3\/SNAT3 glutamine transporter. Channels 10, 440\u2013452 (2016).","journal-title":"Channels"},{"key":"1513_CR150","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/brain\/awab369","volume":"145","author":"D Marafi","year":"2022","unstructured":"Marafi, D. et al. Biallelic variants in SLC38A3 encoding a glutamine transporter cause epileptic encephalopathy. Brain 145, 909\u2013924 (2022).","journal-title":"Brain"},{"key":"1513_CR151","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neubiorev.2020.07.025","volume":"118","author":"BL Marques","year":"2020","unstructured":"Marques, B. L. et al. Neurobiology of glycine transporters: from molecules to behavior. Neurosci. Biobehav. Rev. 118, 97\u2013110 (2020).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1513_CR152","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuropharm.2015.08.031","volume":"99","author":"H-Y Shen","year":"2015","unstructured":"Shen, H.-Y. et al. Glycine transporter 1 is a target for the treatment of epilepsy. Neuropharmacology 99, 554\u2013565 (2015).","journal-title":"Neuropharmacology"},{"key":"1513_CR153","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1248\/bpb.b15-00501","volume":"39","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. A highly selective inhibitor of glycine transporter-1 elevates the threshold for maximal electroshock-induced tonic seizure in mice. Biol. Pharm. Bull. 39, 174\u2013180 (2016).","journal-title":"Biol. Pharm. Bull."},{"key":"1513_CR154","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","volume":"98","author":"A Reiner","year":"2018","unstructured":"Reiner, A. & Levitz, J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron 98, 1080\u20131098 (2018).","journal-title":"Neuron"},{"key":"1513_CR155","doi-asserted-by":"publisher","first-page":"9607","DOI":"10.3390\/ijms21249607","volume":"21","author":"AC Todd","year":"2020","unstructured":"Todd, A. C. & Hardingham, G. E. The regulation of astrocytic glutamate transporters in health and neurodegenerative diseases. Int. J. Mol. Sci. 21, 9607 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1513_CR156","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/epi.17154","volume":"63","author":"P Kovermann","year":"2022","unstructured":"Kovermann, P., Kolobkova, Y., Franzen, A. & Fahlke, C. Mutations associated with epileptic encephalopathy modify EAAT2 anion channel function. Epilepsia 63, 388\u2013401 (2022).","journal-title":"Epilepsia"},{"key":"1513_CR157","first-page":"77","volume":"14","author":"MJ Falk","year":"2014","unstructured":"Falk, M. J. et al. AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-acetylaspartate. JIMD Rep. 14, 77\u201385 (2014).","journal-title":"JIMD Rep."},{"key":"1513_CR158","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-319-55769-4_16","volume":"16","author":"M Damgaard","year":"2017","unstructured":"Damgaard, M. et al. Development of non-GAT1-selective inhibitors: challenges and achievements. Adv. Neurobiol. 16, 315\u2013332 (2017).","journal-title":"Adv. Neurobiol."},{"key":"1513_CR159","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1177\/1535370221989263","volume":"246","author":"SM Sears","year":"2021","unstructured":"Sears, S. M. & Hewett, S. J. Influence of glutamate and GABA transport on brain excitatory\/inhibitory balance. Exp. Biol. Med. 246, 1069\u20131083 (2021).","journal-title":"Exp. Biol. Med."},{"key":"1513_CR160","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.pharmthera.2009.11.007","volume":"125","author":"KK Madsen","year":"2010","unstructured":"Madsen, K. K., White, H. S. & Schousboe, A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther. 125, 394\u2013401 (2010).","journal-title":"Pharmacol. Ther."},{"key":"1513_CR161","doi-asserted-by":"publisher","first-page":"fcae110","DOI":"10.1093\/braincomms\/fcae110","volume":"6","author":"W Shen","year":"2024","unstructured":"Shen, W. et al. \u03b3-Aminobutyric acid transporter and GABAA receptor mechanisms in Slc6a1+\/A288V and Slc6a1+\/S295L mice associated with developmental and epileptic encephalopathies. Brain Commun. 6, fcae110 (2024).","journal-title":"Brain Commun."},{"key":"1513_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9038","volume":"6","author":"T St\u00f6dberg","year":"2015","unstructured":"St\u00f6dberg, T. et al. Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat. Commun. 6, 8038 (2015).","journal-title":"Nat. Commun."},{"key":"1513_CR163","doi-asserted-by":"publisher","first-page":"100957","DOI":"10.1016\/j.xcrm.2023.100957","volume":"4","author":"R Jarvis","year":"2023","unstructured":"Jarvis, R. et al. Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice. Cell Rep. Med. 4, 100957 (2023).","journal-title":"Cell Rep. Med."},{"key":"1513_CR164","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ana.26485","volume":"92","author":"K Platzer","year":"2022","unstructured":"Platzer, K. et al. De novo missense variants in SLC32A1 cause a developmental and epileptic encephalopathy due to impaired gabaergic neurotransmission. Ann. Neurol. 92, 958\u2013973 (2022).","journal-title":"Ann. Neurol."},{"key":"1513_CR165","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12041-015-0567-0","volume":"94","author":"J Li","year":"2015","unstructured":"Li, J. et al. Combined effect between two functional polymorphisms of SLC6A12 gene is associated with temporal lobe epilepsy. J. Genet. 94, 637\u2013642 (2015).","journal-title":"J. Genet."},{"key":"1513_CR166","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.freeradbiomed.2008.12.018","volume":"46","author":"FE Harrison","year":"2009","unstructured":"Harrison, F. E. & May, J. M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic. Biol. Med. 46, 719\u2013730 (2009).","journal-title":"Free Radic. Biol. Med."},{"key":"1513_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2007.10.007","volume":"89","author":"LFL Santos","year":"2008","unstructured":"Santos, L. F. L., Freitas, R. L. M., Xavier, S. M. L., Saldanha, G. B. & Freitas, R. M. Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol. Biochem. Behav. 89, 1\u20135 (2008).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1513_CR168","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/cn500042t","volume":"5","author":"G Zheng","year":"2014","unstructured":"Zheng, G. et al. Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem. Neurosci. 5, 658\u2013665 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"1513_CR169","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1007\/s12035-017-0762-5","volume":"55","author":"K Salazar","year":"2018","unstructured":"Salazar, K. et al. SVCT2 expression and function in reactive astrocytes is a common event in different brain pathologies. Mol. Neurobiol. 55, 5439\u20135452 (2018).","journal-title":"Mol. Neurobiol."},{"key":"1513_CR170","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto, M. R., Higley, M. J. & Mineur, Y. S. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116\u2013129 (2012).","journal-title":"Neuron"},{"key":"1513_CR171","doi-asserted-by":"publisher","first-page":"116617","DOI":"10.1016\/j.celrep.2025.116617","volume":"44","author":"Q Chen","year":"2025","unstructured":"Chen, Q. et al. SLC44A1 deficiency impedes myelin development in the central nervous system. Cell Rep. 44, 116617 (2025).","journal-title":"Cell Rep."},{"key":"1513_CR172","doi-asserted-by":"publisher","unstructured":"Calame, D. G. et al. Biallelic variation in the choline and ethanolamine transporter FLVCR1 underlies a pleiotropic disease spectrum from adult neurodegeneration to severe developmental disorders. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.02.09.24302464 (2024).","DOI":"10.1101\/2024.02.09.24302464"},{"key":"1513_CR173","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41586-024-07444-7","volume":"630","author":"K Ri","year":"2024","unstructured":"Ri, K. et al. Molecular mechanism of choline and ethanolamine transport in humans. Nature 630, 501\u2013508 (2024).","journal-title":"Nature"},{"key":"1513_CR174","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1474-4422(08)70092-9","volume":"7","author":"EG Neal","year":"2008","unstructured":"Neal, E. G. et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 7, 500\u2013506 (2008).","journal-title":"Lancet Neurol."},{"key":"1513_CR175","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/BJ20091515","volume":"425","author":"MJ Ovens","year":"2010","unstructured":"Ovens, M. J., Davies, A. J., Wilson, M. C., Murray, C. M. & Halestrap, A. P. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem. J. 425, 523\u2013530 (2010).","journal-title":"Biochem. J."},{"key":"1513_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05054-0","volume":"7","author":"LS Forero-Quintero","year":"2017","unstructured":"Forero-Quintero, L. S., Deitmer, J. W. & Becker, H. M. Reduction of epileptiform activity in ketogenic mice: The role of monocarboxylate transporters. Sci. Rep. 7, 4900 (2017).","journal-title":"Sci. Rep."},{"key":"1513_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08314-4","volume":"17","author":"SN Barile","year":"2025","unstructured":"Barile, S. N. et al. Combined ketone body and glutamine supplementation restores aerobic energy production in AGC1-deficient neuronal progenitors. Cell Death Dis. 17, 120 (2025).","journal-title":"Cell Death Dis."},{"key":"1513_CR178","doi-asserted-by":"publisher","first-page":"9293","DOI":"10.1523\/JNEUROSCI.0711-20.2020","volume":"40","author":"I P\u00e9rez-Li\u00e9bana","year":"2020","unstructured":"P\u00e9rez-Li\u00e9bana, I. et al. \u03b2OHB protective pathways in aralar-KO neurons and brain: an alternative to ketogenic diet. J. Neurosci. 40, 9293\u20139305 (2020).","journal-title":"J. Neurosci."},{"key":"1513_CR179","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.biopsych.2009.08.042","volume":"67","author":"T Sakurai","year":"2010","unstructured":"Sakurai, T. et al. Slc25a12 disruption alters myelination and neurofilaments: a model for a hypomyelination syndrome and childhood neurodevelopmental disorders. Biol. Psychiatry 67, 887\u2013894 (2010).","journal-title":"Biol. Psychiatry"},{"key":"1513_CR180","doi-asserted-by":"publisher","first-page":"ENEURO.0341","DOI":"10.1523\/ENEURO.0341-16.2017","volume":"4","author":"TS McDonald","year":"2017","unstructured":"McDonald, T. S., Carrasco-Pozo, C., Hodson, M. P. & Borges, K. Alterations in cytosolic and mitochondrial [U-13C]glucose metabolism in a chronic epilepsy mouse model. eNeuro 4, ENEURO.0341\u201316 (2017).","journal-title":"eNeuro"},{"key":"1513_CR181","doi-asserted-by":"publisher","first-page":"105018","DOI":"10.1016\/j.nbd.2020.105018","volume":"143","author":"C Henke","year":"2020","unstructured":"Henke, C. et al. Disruption of the sodium-dependent citrate transporter SLC13A5 in mice causes alterations in brain citrate levels and neuronal network excitability in the hippocampus. Neurobiol. Dis. 143, 105018 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1513_CR182","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ymgme.2017.06.009","volume":"121","author":"MN Bainbridge","year":"2017","unstructured":"Bainbridge, M. N. et al. Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle. Mol. Genet. Metab. 121, 314\u2013319 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"1513_CR183","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1021\/acs.chemrev.0c00529","volume":"121","author":"V Jaramillo-Martinez","year":"2021","unstructured":"Jaramillo-Martinez, V., Urbatsch, I. L. & Ganapathy, V. Functional distinction between human and mouse sodium-coupled citrate transporters and its biologic significance: an attempt for structural basis using a homology modeling approach. Chem. Rev. 121, 5359\u20135377 (2021).","journal-title":"Chem. Rev."},{"key":"1513_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29547-8","volume":"8","author":"S Selch","year":"2018","unstructured":"Selch, S. et al. Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism. Sci. Rep. 8, 11330 (2018).","journal-title":"Sci. Rep."},{"key":"1513_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03397-y","volume":"23","author":"SI Hussain","year":"2023","unstructured":"Hussain, S. I. et al. Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability. BMC Neurol. 23, 353 (2023).","journal-title":"BMC Neurol."},{"key":"1513_CR186","first-page":"111","volume":"19","author":"P Prasun","year":"2015","unstructured":"Prasun, P. et al. Expanding the clinical spectrum of mitochondrial citrate carrier (SLC25A1) deficiency: facial dysmorphism in siblings with epileptic encephalopathy and combined D,L-2-hydroxyglutaric aciduria. JIMD Rep. 19, 111\u2013115 (2015).","journal-title":"JIMD Rep."},{"key":"1513_CR187","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541\u2013553 (2005).","journal-title":"NeuroRx"},{"key":"1513_CR188","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22064","volume":"544","author":"JC Canul-Tec","year":"2017","unstructured":"Canul-Tec, J. C. et al. Structure and allosteric inhibition of excitatory amino acid transporter 1. Nature 544, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"1513_CR189","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tips.2020.04.006","volume":"41","author":"M Niello","year":"2020","unstructured":"Niello, M., Gradisch, R., Loland, C. J., Stockner, T. & Sitte, H. H. Allosteric modulation of neurotransmitter transporters as a therapeutic strategy. Trends Pharmacol. Sci. 41, 446\u2013463 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"1513_CR190","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.chembiol.2020.04.003","volume":"27","author":"A Bensimon","year":"2020","unstructured":"Bensimon, A. et al. Targeted degradation of SLC transporters reveals amenability of multi-pass transmembrane proteins to ligand-induced proteolysis. Cell Chem. Biol. 27, 728\u2013739 (2020).","journal-title":"Cell Chem. Biol."},{"key":"1513_CR191","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s44320-025-00109-1","volume":"21","author":"F Frommelt","year":"2025","unstructured":"Frommelt, F. et al. The solute carrier superfamily interactome. Mol. Syst. Biol. 21, 632\u2013675 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"1513_CR192","doi-asserted-by":"publisher","first-page":"eadt1630","DOI":"10.1126\/science.adt1630","volume":"390","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Predicting protein-protein interactions in the human proteome. Science 390, eadt1630 (2025).","journal-title":"Science"},{"key":"1513_CR193","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41586-020-2282-0","volume":"581","author":"LX Heinz","year":"2020","unstructured":"Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature 581, 316\u2013322 (2020).","journal-title":"Nature"},{"key":"1513_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42070-3","volume":"14","author":"A Boeszoermenyi","year":"2023","unstructured":"Boeszoermenyi, A. et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat. Commun. 14, 6626 (2023).","journal-title":"Nat. Commun."},{"key":"1513_CR195","doi-asserted-by":"publisher","first-page":"101789","DOI":"10.1016\/j.xcrm.2024.101789","volume":"5","author":"Y-H Lin","year":"2024","unstructured":"Lin, Y.-H. et al. Disrupting stroke-induced GAT-1-syntaxin1A interaction promotes functional recovery after stroke. Cell Rep. Med. 5, 101789 (2024).","journal-title":"Cell Rep. Med."},{"key":"1513_CR196","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201906076","volume":"219","author":"J Amick","year":"2020","unstructured":"Amick, J., Tharkeshwar, A. K., Talaia, G. & Ferguson, S. M. PQLC2 recruits the C9orf72 complex to lysosomes in response to cationic amino acid starvation. J. Cell Biol. 219, e201906076 (2020).","journal-title":"J. Cell Biol."},{"key":"1513_CR197","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","volume":"14","author":"R Balendra","year":"2018","unstructured":"Balendra, R. & Isaacs, A. M. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 14, 544\u2013558 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR198","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature14107","volume":"519","author":"M Rebsamen","year":"2015","unstructured":"Rebsamen, M. et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519, 477\u2013481 (2015).","journal-title":"Nature"},{"key":"1513_CR199","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1126\/science.1257132","volume":"347","author":"S Wang","year":"2015","unstructured":"Wang, S. et al. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347, 188\u2013194 (2015).","journal-title":"Science"},{"key":"1513_CR200","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202503231","volume":"8","author":"N Rezagholizadeh","year":"2025","unstructured":"Rezagholizadeh, N. et al. SLC38A9 is directly involved in Tat-induced endolysosome dysfunction and senescence in astrocytes. Life Sci. Alliance 8, e202503231 (2025).","journal-title":"Life Sci. Alliance"},{"key":"1513_CR201","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","volume":"93","author":"FM Menzies","year":"2017","unstructured":"Menzies, F. M. et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93, 1015\u20131034 (2017).","journal-title":"Neuron"},{"key":"1513_CR202","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2017.09.046","volume":"171","author":"GA Wyant","year":"2017","unstructured":"Wyant, G. A. et al. mTORC1 activator SLC38A9 is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell 171, 642\u2013654 (2017).","journal-title":"Cell"},{"key":"1513_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21841-w","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat. Commun. 12, 1589 (2021).","journal-title":"Nat. Commun."},{"key":"1513_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05866-5","volume":"15","author":"Q Sun","year":"2025","unstructured":"Sun, Q. et al. SLC10A3 regulates ferroptosis of glioblastoma through the STAT3\/GPX4 pathway. Sci. Rep. 15, 21259 (2025).","journal-title":"Sci. Rep."},{"key":"1513_CR205","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neuron.2013.07.043","volume":"80","author":"Q Ouyang","year":"2013","unstructured":"Ouyang, Q. et al. Christianson syndrome protein NHE6 modulates TrkB endosomal signaling required for neuronal circuit development. Neuron 80, 97\u2013112 (2013).","journal-title":"Neuron"},{"key":"1513_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06292-z","volume":"15","author":"M Ramos-Brossier","year":"2024","unstructured":"Ramos-Brossier, M. et al. Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability. Cell Death Dis. 15, 20 (2024).","journal-title":"Cell Death Dis."},{"key":"1513_CR207","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41580-021-00413-2","volume":"23","author":"RS Hegde","year":"2022","unstructured":"Hegde, R. S. & Keenan, R. J. The mechanisms of integral membrane protein biogenesis. Nat. Rev. Mol. Cell Biol. 23, 107\u2013124 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1513_CR208","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41589-022-01002-w","volume":"18","author":"H-K Choi","year":"2022","unstructured":"Choi, H.-K. et al. Evolutionary balance between foldability and functionality of a glucose transporter. Nat. Chem. Biol. 18, 713\u2013723 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1513_CR209","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.56889","volume":"9","author":"PT McGilvray","year":"2020","unstructured":"McGilvray, P. T. et al. An ER translocon for multi-pass membrane protein biogenesis. eLife 9, e56889 (2020).","journal-title":"eLife"},{"key":"1513_CR210","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1042\/BCJ20210644","volume":"478","author":"PG Needham","year":"2021","unstructured":"Needham, P. G. et al. SLC26A9 is selected for endoplasmic reticulum associated degradation (ERAD) via Hsp70-dependent targeting of the soluble STAS domain. Biochem. J. 478, 4203\u20134220 (2021).","journal-title":"Biochem. J."},{"key":"1513_CR211","doi-asserted-by":"publisher","first-page":"106150","DOI":"10.1016\/j.isci.2023.106150","volume":"26","author":"SJ Qualls-Histed","year":"2023","unstructured":"Qualls-Histed, S. J., Nielsen, C. P. & MacGurn, J. A. Lysosomal trafficking of the glucose transporter GLUT1 requires sequential regulation by TXNIP and ubiquitin. iScience 26, 106150 (2023).","journal-title":"iScience"},{"key":"1513_CR212","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","volume":"187","author":"F Liu","year":"2024","unstructured":"Liu, F. et al. Structure-based discovery of CFTR potentiators and inhibitors. Cell 187, 3712\u20133725 (2024).","journal-title":"Cell"},{"key":"1513_CR213","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1021\/acschembio.4c00571","volume":"19","author":"LN Gechijian","year":"2024","unstructured":"Gechijian, L. N. et al. Novel corrector for variants of SLC6A8: a therapeutic opportunity for creatine transporter deficiency. ACS Chem. Biol. 19, 2372\u20132382 (2024).","journal-title":"ACS Chem. Biol."},{"key":"1513_CR214","doi-asserted-by":"publisher","first-page":"13754","DOI":"10.1021\/jacs.5c01889","volume":"147","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. USP28-based deubiquitinase-targeting chimeras for cancer treatment. J. Am. Chem. Soc. 147, 13754\u201313763 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"1513_CR215","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41586-024-07950-8","volume":"633","author":"CSC Ng","year":"2024","unstructured":"Ng, C. S. C., Liu, A., Cui, B. & Banik, S. M. Targeted protein relocalization via protein transport coupling. Nature 633, 941\u2013951 (2024).","journal-title":"Nature"},{"key":"1513_CR216","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cells12010039","volume":"12","author":"TJF Angenoorth","year":"2022","unstructured":"Angenoorth, T. J. F. et al. Rescue of misfolded organic cation transporter 3 variants. Cells 12, 39 (2022).","journal-title":"Cells"},{"key":"1513_CR217","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1021\/acs.jmedchem.2c01572","volume":"66","author":"IC Fontana","year":"2023","unstructured":"Fontana, I. C. et al. A medicinal chemistry perspective on excitatory amino acid transporter 2 dysfunction in neurodegenerative diseases. J. Med. Chem. 66, 2330\u20132346 (2023).","journal-title":"J. Med. Chem."},{"key":"1513_CR218","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","volume":"23","author":"P Klein","year":"2024","unstructured":"Klein, P., Kaminski, R. M., Koepp, M. & L\u00f6scher, W. New epilepsy therapies in development. Nat. Rev. Drug Discov. 23, 682\u2013708 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR219","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1021\/acs.jmedchem.2c00534","volume":"65","author":"M Abram","year":"2022","unstructured":"Abram, M. et al. Discovery of (R)-N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a novel orally bioavailable EAAT2 modulator with drug-like properties and potent antiseizure activity in vivo. J. Med. Chem. 65, 11703\u201311725 (2022).","journal-title":"J. Med. Chem."},{"key":"1513_CR220","doi-asserted-by":"publisher","first-page":"912812","DOI":"10.3389\/fcell.2022.912812","volume":"10","author":"FJ Prael Iii","year":"2022","unstructured":"Prael Iii, F. J. et al. Discovery of small molecule KCC2 potentiators which attenuate in vitro seizure-like activity in cultured neurons. Front. Cell Dev. Biol. 10, 912812 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1513_CR221","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1164\/rccm.202402-0389CI","volume":"210","author":"JC Davies","year":"2024","unstructured":"Davies, J. C. et al. Lentiviral gene therapy for cystic fibrosis: a promising approach and first-in-human trial. Am. J. Respir. Crit. Care Med. 210, 1398\u20131408 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1513_CR222","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182235","volume":"135","author":"W Guo","year":"2024","unstructured":"Guo, W. et al. AAV9\/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1-\/- mice. J. Clin. Invest. 135, e182235 (2024).","journal-title":"J. Clin. Invest."},{"key":"1513_CR223","doi-asserted-by":"publisher","DOI":"10.1172\/JCI197503","volume":"136","author":"LE Bailey","year":"2026","unstructured":"Bailey, L. E. et al. AAV-mediated gene therapy for SLC13A5 citrate transporter disorder rescues epileptic and metabolic phenotypes. J. Clin. Invest. 136, e197503 (2026).","journal-title":"J. Clin. Invest."},{"key":"1513_CR224","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.11.659105","author":"AC Huang","year":"2025","unstructured":"Huang, A. C. et al. X-Atlas\/Orion: Genome-wide perturb-seq datasets via a scalable fix-cryopreserve platform for training dose-dependent biological foundation models. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.11.659105 (2025).","journal-title":"bioRxiv"},{"key":"1513_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38582-7","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates. Nat. Commun. 14, 3345 (2023).","journal-title":"Nat. Commun."},{"key":"1513_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57481-7","volume":"16","author":"A Greer-Short","year":"2025","unstructured":"Greer-Short, A. et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat. Commun. 16, 2196 (2025).","journal-title":"Nat. Commun."},{"key":"1513_CR227","doi-asserted-by":"publisher","first-page":"101588","DOI":"10.1016\/j.omtm.2025.101588","volume":"33","author":"S Chornyy","year":"2025","unstructured":"Chornyy, S. et al. Comparative analysis of cell-specific promoters in AAV9-mediated gene therapy targeting the central nervous system. Mol. Ther. Methods Clin. Dev. 33, 101588 (2025).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1513_CR228","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188703","volume":"135","author":"H Lerche","year":"2025","unstructured":"Lerche, H., Hedrich, U. B. & Wuttke, T. V. Gene-replacement therapy in neurodevelopmental disorders: progress and challenges. J. Clin. Invest. 135, e188703 (2025).","journal-title":"J. Clin. Invest."},{"key":"1513_CR229","doi-asserted-by":"publisher","first-page":"1401599","DOI":"10.3389\/fphar.2024.1401599","volume":"15","author":"D Digles","year":"2024","unstructured":"Digles, D. et al. Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily. Front. Pharmacol. 15, 1401599 (2024).","journal-title":"Front. Pharmacol."},{"key":"1513_CR230","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrd2552","volume":"7","author":"J Dunlop","year":"2008","unstructured":"Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D. & Arias, R. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov. 7, 358\u2013368 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR231","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-022-00753-3","volume":"19","author":"M Perovnik","year":"2023","unstructured":"Perovnik, M., Rus, T., Schindlbeck, K. A. & Eidelberg, D. Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nat. Rev. Neurol. 19, 73\u201390 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR232","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-022-00723-9","volume":"18","author":"OL Eichm\u00fcller","year":"2022","unstructured":"Eichm\u00fcller, O. L. & Knoblich, J. A. Human cerebral organoids \u2014 a new tool for clinical neurology research. Nat. Rev. Neurol. 18, 661\u2013680 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR233","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41582-020-0373-z","volume":"16","author":"M Kampmann","year":"2020","unstructured":"Kampmann, M. CRISPR-based functional genomics for neurological disease. Nat. Rev. Neurol. 16, 465\u2013480 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR234","doi-asserted-by":"publisher","first-page":"eabi8654","DOI":"10.1126\/science.abi8654","volume":"377","author":"YA Cooper","year":"2022","unstructured":"Cooper, Y. A. et al. Functional regulatory variants implicate distinct transcriptional networks in dementia. Science 377, eabi8654 (2022).","journal-title":"Science"},{"key":"1513_CR235","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41573-025-01317-y","volume":"25","author":"D Wang","year":"2025","unstructured":"Wang, D., Villenave, R., Stokar-Regenscheit, N. & Clevers, H. Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges. Nat. Rev. Drug Discov. 25, 204\u2013226\u00a0(2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1513_CR236","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41593-025-02118-7","volume":"29","author":"CR Bye","year":"2026","unstructured":"Bye, C. R. et al. Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy. Nat. Neurosci. 29, 40\u201352 (2026).","journal-title":"Nat. Neurosci."},{"key":"1513_CR237","doi-asserted-by":"publisher","first-page":"eadn8417","DOI":"10.1126\/scitranslmed.adn8417","volume":"17","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Patient-derived models of UBA5-associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenues. Sci. Transl Med. 17, eadn8417 (2025).","journal-title":"Sci. Transl Med."},{"key":"1513_CR238","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-023-06473-y","volume":"621","author":"C Li","year":"2023","unstructured":"Li, C. et al. Single-cell brain organoid screening identifies developmental defects in autism. Nature 621, 373\u2013380 (2023).","journal-title":"Nature"},{"key":"1513_CR239","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s44320-025-00105-5","volume":"21","author":"G Wolf","year":"2025","unstructured":"Wolf, G. et al. The genetic interaction map of the human solute carrier superfamily. Mol. Syst. Biol. 21, 531\u2013559 (2025).","journal-title":"Mol. Syst. Biol."},{"key":"1513_CR240","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.stem.2021.09.002","volume":"28","author":"C Lentini","year":"2021","unstructured":"Lentini, C. et al. Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy. Cell Stem Cell 28, 2104\u20132121 (2021).","journal-title":"Cell Stem Cell"},{"key":"1513_CR241","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.stem.2013.11.006","volume":"13","author":"JD Miller","year":"2013","unstructured":"Miller, J. D. et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691\u2013705 (2013).","journal-title":"Cell Stem Cell"},{"key":"1513_CR242","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.stemcr.2019.01.020","volume":"12","author":"H Kim","year":"2019","unstructured":"Kim, H. et al. Modeling G2019S-LRRK2 sporadic Parkinson\u2019s disease in 3D midbrain organoids. Stem Cell Rep. 12, 518\u2013531 (2019).","journal-title":"Stem Cell Rep."},{"key":"1513_CR243","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19264-0","volume":"11","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer\u2019s disease patient iPSC-derived cerebral organoids. Nat. Commun. 11, 5540 (2020).","journal-title":"Nat. Commun."},{"key":"1513_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19136-7","volume":"11","author":"IF Schene","year":"2020","unstructured":"Schene, I. F. et al. Prime editing for functional repair in patient-derived disease models. Nat. Commun. 11, 5352 (2020).","journal-title":"Nat. Commun."},{"key":"1513_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19293-3","volume":"12","author":"JO Aceves","year":"2022","unstructured":"Aceves, J. O. et al. 3D proximal tubule-on-chip model derived from kidney organoids with improved drug uptake. Sci. Rep. 12, 14997 (2022).","journal-title":"Sci. Rep."},{"key":"1513_CR246","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.stem.2024.03.004","volume":"31","author":"JD Lai","year":"2024","unstructured":"Lai, J. D. et al. KCNJ2 inhibition mitigates mechanical injury in a human brain organoid model of traumatic brain injury. Cell Stem Cell 31, 519\u2013536 (2024).","journal-title":"Cell Stem Cell"},{"key":"1513_CR247","doi-asserted-by":"publisher","first-page":"102725","DOI":"10.1016\/j.xpro.2023.102725","volume":"4","author":"B Al-Mhanawi","year":"2023","unstructured":"Al-Mhanawi, B. et al. Protocol for generating embedding-free brain organoids enriched with oligodendrocytes. STAR Protoc. 4, 102725 (2023).","journal-title":"STAR Protoc."},{"key":"1513_CR248","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.70005","volume":"58","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Human midbrain organoids enriched with dopaminergic neurons for long-term functional evaluation. Cell Prolif. 58, e70005 (2025).","journal-title":"Cell Prolif."},{"key":"1513_CR249","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.stem.2024.04.019","volume":"31","author":"L Dao","year":"2024","unstructured":"Dao, L. et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids. Cell Stem Cell 31, 818\u2013833 (2024).","journal-title":"Cell Stem Cell"},{"key":"1513_CR250","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-025-09997-7","volume":"651","author":"JW Ding","year":"2026","unstructured":"Ding, J. W. et al. Dissecting gene regulatory networks governing human cortical cell fate. Nature 651, 732\u2013742 (2026).","journal-title":"Nature"},{"key":"1513_CR251","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41593-023-01399-0","volume":"26","author":"A Jourdon","year":"2023","unstructured":"Jourdon, A. et al. Modeling idiopathic autism in forebrain organoids reveals an imbalance of excitatory cortical neuron subtypes during early neurogenesis. Nat. Neurosci. 26, 1505\u20131515 (2023).","journal-title":"Nat. Neurosci."},{"key":"1513_CR252","doi-asserted-by":"publisher","first-page":"114862","DOI":"10.1016\/j.celrep.2024.114862","volume":"43","author":"LAD Bury","year":"2024","unstructured":"Bury, L. A. D., Fu, S. & Wynshaw-Boris, A. Neuronal lineage tracing from progenitors in\u00a0human cortical organoids reveals mechanisms of neuronal production, diversity, and disease. Cell Rep. 43, 114862 (2024).","journal-title":"Cell Rep."},{"key":"1513_CR253","doi-asserted-by":"publisher","unstructured":"Jourdon, A. et al. Enhancer-driven gene regulatory network of forebrain human development provides insights into autism. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.09.06.555206 (2025).","DOI":"10.1101\/2023.09.06.555206"},{"key":"1513_CR254","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"W-T Chen","year":"2020","unstructured":"Chen, W.-T. et al. Spatial transcriptomics and in situ sequencing to study Alzheimer\u2019s disease. Cell 182, 976\u2013991 (2020).","journal-title":"Cell"},{"key":"1513_CR255","doi-asserted-by":"publisher","first-page":"113784","DOI":"10.1016\/j.celrep.2024.113784","volume":"43","author":"P Kilfeather","year":"2024","unstructured":"Kilfeather, P. et al. Single-cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, aging, and disease. Cell Rep. 43, 113784 (2024).","journal-title":"Cell Rep."},{"key":"1513_CR256","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s44477-025-00002-z","volume":"1","author":"DR Avey","year":"2025","unstructured":"Avey, D. R. et al. Uncovering plaque-glia niches in human Alzheimer\u2019s disease brains using spatial transcriptomics. Mol. Neurodegener. Adv. 1, 2 (2025).","journal-title":"Mol. Neurodegener. Adv."},{"key":"1513_CR257","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-025-09225-2","volume":"644","author":"M Kuehl","year":"2025","unstructured":"Kuehl, M. et al. Pathology-oriented multiplexing enables integrative disease mapping. Nature 644, 516\u2013526 (2025).","journal-title":"Nature"},{"key":"1513_CR258","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.01.651759","author":"D Kong","year":"2025","unstructured":"Kong, D. et al. Spatial profiling of chromatin accessibility reveals alteration of glial cells in Alzheimer\u2019s disease mouse brain. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.01.651759 (2025).","journal-title":"bioRxiv"},{"key":"1513_CR259","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41593-025-01933-2","volume":"28","author":"PR Nano","year":"2025","unstructured":"Nano, P. R. et al. Integrated analysis of molecular atlases unveils modules driving developmental cell subtype specification in the human cortex. Nat. Neurosci. 28, 949\u2013963 (2025).","journal-title":"Nat. Neurosci."},{"key":"1513_CR260","doi-asserted-by":"publisher","first-page":"eadi5199","DOI":"10.1126\/science.adi5199","volume":"384","author":"PS Emani","year":"2024","unstructured":"Emani, P. S. et al. Single-cell genomics and regulatory networks for 388 human brains. Science 384, eadi5199 (2024).","journal-title":"Science"},{"key":"1513_CR261","doi-asserted-by":"publisher","first-page":"100263","DOI":"10.1016\/j.xgen.2023.100263","volume":"3","author":"AG Anderson","year":"2023","unstructured":"Anderson, A. G. et al. Single nucleus multiomics identifies ZEB1 and MAFB as candidate regulators of Alzheimer\u2019s disease-specific cis-regulatory elements. Cell Genomics 3, 100263 (2023).","journal-title":"Cell Genomics"},{"key":"1513_CR262","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/s41593-024-01774-5","volume":"27","author":"MI Gabitto","year":"2024","unstructured":"Gabitto, M. I. et al. Integrated multimodal cell atlas of Alzheimer\u2019s disease. Nat. Neurosci. 27, 2366\u20132383 (2024).","journal-title":"Nat. Neurosci."},{"key":"1513_CR263","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.1016\/j.cell.2025.08.038","volume":"188","author":"E Wang","year":"2025","unstructured":"Wang, E. et al. Multiscale proteomic modeling reveals protein networks driving Alzheimer\u2019s disease pathogenesis. Cell 188, 6186\u20136204 (2025).","journal-title":"Cell"},{"key":"1513_CR264","doi-asserted-by":"publisher","first-page":"eabo1997","DOI":"10.1126\/scitranslmed.abo1997","volume":"16","author":"B Zhu","year":"2024","unstructured":"Zhu, B. et al. Single-cell transcriptomic and proteomic analysis of Parkinson\u2019s disease brains. Sci. Transl Med. 16, eabo1997 (2024).","journal-title":"Sci. Transl Med."},{"key":"1513_CR265","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41589-022-01012-8","volume":"18","author":"M Choe","year":"2022","unstructured":"Choe, M. & Titov, D. V. Genetically encoded tools for measuring and manipulating metabolism. Nat. Chem. Biol. 18, 451\u2013460 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1513_CR266","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53917","volume":"9","author":"R Arce-Molina","year":"2020","unstructured":"Arce-Molina, R. et al. A highly responsive pyruvate sensor reveals pathway-regulatory role of the mitochondrial pyruvate carrier MPC. eLife 9, e53917 (2020).","journal-title":"eLife"},{"key":"1513_CR267","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1021\/acscentsci.0c00518","volume":"6","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Shen, Y., Wen, Y. & Campbell, R. E. High-performance intensiometric direct- and inverse-response genetically encoded biosensors for citrate. ACS Cent. Sci. 6, 1441\u20131450 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1513_CR268","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.chembiol.2024.05.002","volume":"31","author":"L Hellweg","year":"2024","unstructured":"Hellweg, L. et al. AspSnFR: a genetically encoded biosensor for real-time monitoring of aspartate in live cells. Cell Chem. Biol. 31, 1529\u20131541 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1513_CR269","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1080\/15548627.2020.1771858","volume":"17","author":"AH Ponsford","year":"2021","unstructured":"Ponsford, A. H. et al. Live imaging of intra-lysosome pH in cell lines and primary neuronal culture using a novel genetically encoded biosensor. Autophagy 17, 1500\u20131518 (2021).","journal-title":"Autophagy"},{"key":"1513_CR270","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41589-023-01350-1","volume":"19","author":"L Hellweg","year":"2023","unstructured":"Hellweg, L. et al. A general method for the development of multicolor biosensors with large dynamic ranges. Nat. Chem. Biol. 19, 1147\u20131157 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1513_CR271","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.conb.2020.02.011","volume":"63","author":"D Koveal","year":"2020","unstructured":"Koveal, D., D\u00edaz-Garc\u00eda, C. M. & Yellen, G. Fluorescent biosensors for neuronal metabolism and the challenges of quantitation. Curr. Opin. Neurobiol. 63, 111\u2013121 (2020).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1513_CR272","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.stem.2026.01.007","volume":"33","author":"T Uenaka","year":"2026","unstructured":"Uenaka, T. et al. Prevention of transgene silencing during human pluripotent stem cell differentiation. Cell Stem Cell 33, 517\u2013530 (2026).","journal-title":"Cell Stem Cell"},{"key":"1513_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33348-z","volume":"13","author":"JJ Rennick","year":"2022","unstructured":"Rennick, J. J., Nowell, C. J., Pouton, C. W. & Johnston, A. P. R. Resolving subcellular pH with a quantitative fluorescent lifetime biosensor. Nat. Commun. 13, 6023 (2022).","journal-title":"Nat. Commun."},{"key":"1513_CR274","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41592-023-01863-6","volume":"20","author":"A Aggarwal","year":"2023","unstructured":"Aggarwal, A. et al. Glutamate indicators with improved activation kinetics and localization for imaging synaptic transmission. Nat. Methods 20, 925\u2013934 (2023).","journal-title":"Nat. Methods"},{"key":"1513_CR275","doi-asserted-by":"publisher","first-page":"100904","DOI":"10.1016\/j.crmeth.2024.100904","volume":"4","author":"X Li","year":"2024","unstructured":"Li, X. et al. Elucidating the spatiotemporal dynamics of glucose metabolism with genetically encoded fluorescent biosensors. Cell Rep. Methods 4, 100904 (2024).","journal-title":"Cell Rep. Methods"},{"key":"1513_CR276","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/nm.3356","volume":"19","author":"M Gagnon","year":"2013","unstructured":"Gagnon, M. et al. Chloride extrusion enhancers as novel therapeutics for neurological diseases. Nat. Med. 19, 1524\u20131528 (2013).","journal-title":"Nat. Med."},{"key":"1513_CR277","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.cmet.2015.04.009","volume":"21","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. SoNar, a highly responsive NAD+\/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab. 21, 777\u2013789 (2015).","journal-title":"Cell Metab."},{"key":"1513_CR278","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.chembiol.2025.10.006","volume":"32","author":"RPM Abrams","year":"2025","unstructured":"Abrams, R. P. M. et al. An engineered cysteine sensor optimized for high-throughput screening identifies regulators of intracellular thiol levels. Cell Chem. Biol. 32, 1381\u20131396 (2025).","journal-title":"Cell Chem. Biol."},{"key":"1513_CR279","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.201611654","volume":"149","author":"D Pendin","year":"2017","unstructured":"Pendin, D., Greotti, E., Lefkimmiatis, K. & Pozzan, T. Exploring cells with targeted biosensors. J. Gen. Physiol. 149, 1\u201336 (2017).","journal-title":"J. Gen. Physiol."},{"key":"1513_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37815-z","volume":"14","author":"T Fujii","year":"2023","unstructured":"Fujii, T. et al. Parkinson\u2019s disease-associated ATP13A2\/PARK9 functions as a lysosomal H+,K+-ATPase. Nat. Commun. 14, 2174 (2023).","journal-title":"Nat. Commun."},{"key":"1513_CR281","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.21.609037","author":"R Tamura","year":"2024","unstructured":"Tamura, R. et al. Genetically encoded fluorescent sensors for visualizing polyamine levels, uptake, and distribution. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.08.21.609037 (2024).","journal-title":"bioRxiv"},{"key":"1513_CR282","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01134-7","volume":"14","author":"K Leng","year":"2022","unstructured":"Leng, K. & Kampmann, M. Towards elucidating disease-relevant states of neurons and glia by CRISPR-based functional genomics. Genome Med. 14, 130 (2022).","journal-title":"Genome Med."},{"key":"1513_CR283","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.cmet.2023.03.012","volume":"35","author":"F Suomi","year":"2023","unstructured":"Suomi, F., Rappe, A. & McWilliams, T. G. Metabolic set points of mammalian neurodevelopment. Cell Metab. 35, 553\u2013554 (2023).","journal-title":"Cell Metab."},{"key":"1513_CR284","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41592-022-01743-5","volume":"20","author":"H Tian","year":"2023","unstructured":"Tian, H. et al. Video-based pooled screening yields improved far-red genetically encoded voltage indicators. Nat. Methods 20, 1082\u20131094 (2023).","journal-title":"Nat. Methods"},{"key":"1513_CR285","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41586-023-05828-9","volume":"615","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Fast and sensitive GCaMP calcium indicators for imaging neural populations. Nature 615, 884\u2013891 (2023).","journal-title":"Nature"},{"key":"1513_CR286","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.abm3452","volume":"379","author":"KG Hicks","year":"2023","unstructured":"Hicks, K. G. et al. Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase. Science 379, 996\u20131003 (2023).","journal-title":"Science"},{"key":"1513_CR287","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-025-09326-y","volume":"646","author":"SJ Middleton","year":"2025","unstructured":"Middleton, S. J. et al. SLC45A4 is a pain gene encoding a neuronal polyamine transporter. Nature 646, 404\u2013412 (2025).","journal-title":"Nature"},{"key":"1513_CR288","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62721-x","volume":"16","author":"C Colson","year":"2025","unstructured":"Colson, C. et al. SLC45A4 encodes a peroxisomal putrescine transporter that promotes GABA de novo synthesis. Nat. Commun. 16, 10198 (2025).","journal-title":"Nat. Commun."},{"key":"1513_CR289","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1513_CR290","doi-asserted-by":"publisher","first-page":"eadl2528","DOI":"10.1126\/science.adl2528","volume":"384","author":"R Krishna","year":"2024","unstructured":"Krishna, R. et al. Generalized biomolecular modeling and design with RoseTTAFold All-Atom. Science 384, eadl2528 (2024).","journal-title":"Science"},{"key":"1513_CR291","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/09687688.2013.842658","volume":"30","author":"G Rudnick","year":"2013","unstructured":"Rudnick, G. How do transporters couple solute movements? Mol. Membr. Biol. 30, 355\u2013359 (2013).","journal-title":"Mol. Membr. Biol."},{"key":"1513_CR292","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42004-024-01398-7","volume":"7","author":"B Selvam","year":"2024","unstructured":"Selvam, B., Chiang, N. & Shukla, D. Energetics of substrate transport in proton-dependent oligopeptide transporters. Commun. Chem. 7, 309 (2024).","journal-title":"Commun. Chem."},{"key":"1513_CR293","doi-asserted-by":"publisher","unstructured":"Veselu, D.-F., Shoemark, D. K. & van der Kamp, M. W. Influence of disease-causing mutations and ivacaftor on the dynamics of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.07.07.663434 (2025).","DOI":"10.1101\/2025.07.07.663434"},{"key":"1513_CR294","doi-asserted-by":"publisher","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","volume":"381","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).","journal-title":"Science"},{"key":"1513_CR295","doi-asserted-by":"publisher","first-page":"eadx3011","DOI":"10.1126\/sciadv.adx3011","volume":"11","author":"W-A Wang","year":"2025","unstructured":"Wang, W.-A. et al. Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5. Sci. Adv. 11, eadx3011 (2025).","journal-title":"Sci. Adv."},{"key":"1513_CR296","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41586-025-09429-6","volume":"646","author":"M Pacesa","year":"2025","unstructured":"Pacesa, M. et al. One-shot design of functional protein binders with BindCraft. Nature 646, 483\u2013492 (2025).","journal-title":"Nature"},{"key":"1513_CR297","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.cell.2023.04.010","volume":"186","author":"I Singh","year":"2023","unstructured":"Singh, I. et al. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell 186, 2160\u20132175 (2023).","journal-title":"Cell"},{"key":"1513_CR298","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.tibs.2023.05.011","volume":"48","author":"A Schlessinger","year":"2023","unstructured":"Schlessinger, A., Zatorski, N., Hutchinson, K. & Colas, C. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Trends Biochem. Sci. 48, 801\u2013814 (2023).","journal-title":"Trends Biochem. Sci."},{"key":"1513_CR299","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","volume":"17","author":"G Ahn","year":"2021","unstructured":"Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937\u2013946 (2021).","journal-title":"Nat. Chem. Biol."},{"key":"1513_CR300","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41586-024-07966-0","volume":"634","author":"AJ Faure","year":"2024","unstructured":"Faure, A. J. et al. The genetic architecture of protein stability. Nature 634, 995\u20131003 (2024).","journal-title":"Nature"},{"key":"1513_CR301","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.28.625821","author":"T Mighell","year":"2024","unstructured":"Mighell, T. & Lehner, B. A pharmacological chaperone stabilizer rescues the expression of the vast majority of pathogenic variants in a G protein-coupled receptor. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.11.28.625821 (2024).","journal-title":"bioRxiv"},{"key":"1513_CR302","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/bcp.15635","volume":"89","author":"J Gamez","year":"2023","unstructured":"Gamez, J. et al. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington\u2019s disease. Br. J. Clin. Pharmacol. 89, 1656\u20131664 (2023).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1513_CR303","doi-asserted-by":"publisher","first-page":"113718","DOI":"10.1016\/j.ejmech.2021.113718","volume":"224","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. Eur. J. Med. Chem. 224, 113718 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1513_CR304","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.chempr.2020.06.017","volume":"6","author":"A Savardi","year":"2020","unstructured":"Savardi, A. et al. Discovery of a small molecule drug candidate for selective NKCC1 inhibition in brain disorders. Chem 6, 2073\u20132096 (2020).","journal-title":"Chem"},{"key":"1513_CR305","doi-asserted-by":"publisher","first-page":"1503070","DOI":"10.3389\/fnmol.2024.1503070","volume":"17","author":"SD Kadam","year":"2024","unstructured":"Kadam, S. D. & Hegarty, S. V. Development of KCC2 therapeutics to treat neurological disorders. Front. Mol. Neurosci. 17, 1503070 (2024).","journal-title":"Front. Mol. Neurosci."},{"key":"1513_CR306","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2589","volume":"12","author":"P Ioannou","year":"2022","unstructured":"Ioannou, P. et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 12, e2589 (2022).","journal-title":"Brain Behav."},{"key":"1513_CR307","doi-asserted-by":"publisher","first-page":"674483","DOI":"10.3389\/fneur.2021.674483","volume":"12","author":"A Fattorusso","year":"2021","unstructured":"Fattorusso, A. et al. The pharmacoresistant epilepsy: an overview on existent and new emerging therapies. Front. Neurol. 12, 674483 (2021).","journal-title":"Front. Neurol."},{"key":"1513_CR308","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.18632\/oncotarget.23192","volume":"9","author":"MS Kim","year":"2018","unstructured":"Kim, M. S. et al. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 9, 5979\u20135992 (2018).","journal-title":"Oncotarget"},{"key":"1513_CR309","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/s41380-024-02531-7","volume":"29","author":"SA Gaitonde","year":"2024","unstructured":"Gaitonde, S. A. et al. Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor. Mol. Psychiatry 29, 2753\u20132764 (2024).","journal-title":"Mol. Psychiatry"},{"key":"1513_CR310","doi-asserted-by":"publisher","first-page":"107743","DOI":"10.1016\/j.neuropharm.2019.107743","volume":"158","author":"T Gener","year":"2019","unstructured":"Gener, T. et al. Serotonin 5-HT1A, 5-HT2A and dopamine D2 receptors strongly influence prefronto-hippocampal neural networks in alert mice: Contribution to the actions of risperidone. Neuropharmacology 158, 107743 (2019).","journal-title":"Neuropharmacology"},{"key":"1513_CR311","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16476-w","volume":"12","author":"M Zuin","year":"2022","unstructured":"Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L. & Zuliani, G. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci. Rep. 12, 12214 (2022).","journal-title":"Sci. Rep."},{"key":"1513_CR312","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/biomedicines9111689","volume":"9","author":"MP-G Moreta","year":"2021","unstructured":"Moreta, M. P.-G., Burgos-Alonso, N., Torrecilla, M., Marco-Contelles, J. & Bruzos-Cid\u00f3n, C. Efficacy of acetylcholinesterase inhibitors on cognitive function in Alzheimer\u2019s disease. review of reviews. Biomedicines 9, 1689 (2021).","journal-title":"Biomedicines"},{"key":"1513_CR313","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi, F., Bravi, D., Emmi, A. & Antonini, A. Parkinson disease therapy: current strategies and future research priorities. Nat. Rev. Neurol. 20, 695\u2013707 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1513_CR314","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/978-1-62703-017-5_14","volume":"924","author":"G Enkavi","year":"2013","unstructured":"Enkavi, G. et al. Simulation studies of the mechanism of membrane transporters. Methods Mol. Biol. 924, 361\u2013405 (2013).","journal-title":"Methods Mol. Biol."},{"key":"1513_CR315","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/cpt.450","volume":"100","author":"B Bissa","year":"2016","unstructured":"Bissa, B., Beedle, A. M. & Govindarajan, R. Lysosomal solute carrier transporters gain momentum in research. Clin. Pharmacol. Ther. 100, 431\u2013436 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1513_CR316","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088883","volume":"9","author":"AY Ye","year":"2014","unstructured":"Ye, A. Y., Liu, Q.-R., Li, C.-Y., Zhao, M. & Qu, H. Human transporter database: comprehensive knowledge and discovery tools in the human transporter genes. PLoS ONE 9, e88883 (2014).","journal-title":"PLoS ONE"},{"key":"1513_CR317","doi-asserted-by":"publisher","first-page":"dmm048993","DOI":"10.1242\/dmm.048993","volume":"14","author":"L Traxler","year":"2021","unstructured":"Traxler, L. et al. Metabolism navigates neural cell fate in development, aging and neurodegeneration. Dis. Model. Mech. 14, dmm048993 (2021).","journal-title":"Dis. Model. Mech."},{"key":"1513_CR318","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","volume":"26","author":"S Shugarts","year":"2009","unstructured":"Shugarts, S. & Benet, L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 26, 2039\u20132054 (2009).","journal-title":"Pharm. Res."},{"key":"1513_CR319","doi-asserted-by":"publisher","first-page":"168383","DOI":"10.1016\/j.jmb.2023.168383","volume":"436","author":"E Ferrada","year":"2024","unstructured":"Ferrada, E. et al. Experimental and computational analysis of newly identified pathogenic mutations in the creatine transporter SLC6A8. J. Mol. Biol. 436, 168383 (2024).","journal-title":"J. Mol. Biol."},{"key":"1513_CR320","doi-asserted-by":"publisher","first-page":"168665","DOI":"10.1016\/j.jmb.2024.168665","volume":"436","author":"Z Gelov\u00e1","year":"2024","unstructured":"Gelov\u00e1, Z. et al. Protein binder toolbox for studies of solute carrier transporters. J. Mol. Biol. 436, 168665 (2024).","journal-title":"J. Mol. Biol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01513-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01513-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01513-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:02:56Z","timestamp":1788282176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01513-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":320,"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01513-4","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"9 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S.-F. and A.B. are co-authors of patent applications related to SLCs and co-founders of the SLC-focused company Solgate GmbH. A.B. and E.G. are employees of Solgate GmbH.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}